top of page

Our Publications

Recent publications from Feucht & Leibold Labs


Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction

Corina Amor, Inés Fernández-Maestre, ..., Judith Feucht, ..., Michel Sadelain & Scott W. Lowe

Nat. Aging.


Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease

Josef Leibold*#, Kaloyan M. Tsanov*, Corina Amor*, ..., Judith Feucht, ..., Scott W. Lowe#

Nat. Cancer.



LINKing signaling domains to enhance CAR T cells

Philip Bucher & Judith Feucht
Nat. Cancer.


TET2 guards against unchecked BATF3-induced CAR T cell expansion

Nayan Jain*, Zeguo Zhao*, Judith Feucht, ..., Michel Sadelain

Novel extragenic genomic safe harbors for precise therapeutic T cell engineering

Ashlesha Odak, ..., Judith Feucht, ..., Michel Sadelain



Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL

Guillermo Ureña-Bailén, ..., Judith Feucht,  ..., Markus Mezger

Int J Mol Sci.

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Jens Bauer, ..., Philip Bucher, ..., Judith Feucht, ..., Juliane S. Walz 

Nat Commun.

A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear Cell Renal Cell Carcinoma

Phillip M. Rappold, Lynda Vuong, Josef Leibold, ..., A. Ari Hakimi 

Cancer Discov.

Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants

Francisco J. Sánchez-Rivera, Bianca J. Diaz, Edward R. Kastenhuber, Henri Schmidt, Alyna Katti, Margaret Kennedy, Vincent Tem, Yu-Jui Ho, Josef Leibold, ..., ​Lukas E. Dow

Nat Biotechnol.

Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer

Stella V. Paffenholz, ..., Josef Leibold# & Scott W. Lowe#

Proc Natl Acad Sci U S A.

HLA-independent T cell receptors for targeting tumors with low antigen density

Jorge Mansilla-Soto, Justin Eyquem, ..., Judith Feucht, ​..., Michel Sadelain 

Nat Med.

Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections

Tanja A Stief, Theresa Kaeuferle, Thomas R Müller, ..., Judith Feucht, ...,Tobias Feuchtinger

Mol Ther.



Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies

Judith Feucht & Mohamed Abou-El-Enein

Mol Ther.

Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors

Judith Feucht & Michel Sadelain

Immunooncol Technol.

Senolytic CAR T cells reverse senescence-associated pathologies

Corina Amor*, Judith Feucht*, Josef Leibold*, ..., ​Michel Sadelain & Scott W. Lowe 


Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis

Josef Leibold*, Marcus Ruscetti*, Zhen Cao*, ..., Judith Feucht, ..., Charles L. Sawyers & Scott W. Lowe 

Cancer Discov.

Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer

Marcus Ruscetti, John P. Morris IV, Riccardo Mezzadra, James Russell, Josef Leibold, ..., Scott W. Lowe



Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study

Semjon Willier, ..., Judith Feucht, ..., Michaela Döring

BMC Cancer.

Comparison of procalcitonin and C-reactive protein as early diagnostic marker for the identification of transplant-related adverse events after allogeneic hematopoietic stem cell transplantation in pediatric patients

Karin Melanie Cabanillas Stanchi, ..., Judith Feucht, ..., Michaela Döring

J Cancer Res Clin Oncol.

Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies

Karin Melanie Cabanillas Stanchi, Martin Ebinger, ..., Judith Feucht, ..., Michaela Döring

Drug Des Devel Ther.

Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy

Franziska Blaeschke, ..., Judith Feucht, ..., Tobias Feuchtinger


The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase

Viraj R. Sanghvi, Josef Leibold, ..., Hans-Guido Wendel


Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma

Derek Lee, Iris Ming-Jing Xu, David Kung-Chun Chiu, Josef Leibold, ..., Irene Oi-Lin Ng & Carmen Chak-Lui Wong


Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

Judith Feucht*, Jie Sun*, ...Josef Leibold, ..., Michel Sadelain 

Nat Med.


NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination

Marcus Ruscetti*, Josef Leibold*, Matthew J. Bott*, ...Judith Feucht, ..., Scott W. Lowe


Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia

Franziska Blaeschke, ..., Judith Feucht & Tobias Feuchtinger

Cancer Immunol. Immunother.

Quantitative self-assembly prediction yields targeted nanomedicines

Yosi Shamay, ..., Josef Leibold, ..., Daniel A. Heller 

Nat Mater.


Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT

Judith Feucht, ..., Tobias Feuchtinger


For complete publication list see PubMed

bottom of page